Tenax Therapeutics: A Binary Bet With Heavy Downside Likely [Seeking Alpha]
Tenax Therapeutics (TENX) is now covered by Cantor Fitzgerald. They set an "overweight" rating and a $35.00 price target on the stock.
Tenax Therapeutics (TENX) had its price target raised by Guggenheim from $25.00 to $34.00. They now have a "buy" rating on the stock.
Tenax Therapeutics (TENX) was upgraded by Lifesci Capital to "strong-buy".
Tenax Therapeutics (TENX) had its "outperform" rating reaffirmed by William Blair.